Getting innovative new drugs to market faster, more economically and safely is prompting manufacturers to rethink their development strategies and business models to reach patients faster.

Outsourcing to partners who can deliver comprehensive end-to-end drug substance and drug product development across API formulations, biologics, and other complex hard-to-make compounds, has become an increasingly popular strategy for pharma manufacturers.

Delivering these highly specialized services with the capacity required to support new drug projects has prompted growth and consolidation among CMOs and the emergence of both pure-play and integrated CDMOs.

Our whitepaper explores current market dynamics and the latest drug development trends driving these strategic outsourcing decisions.